[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 134
Citations 0
Letters
March 21, 2012

Response to Etanercept in Juvenile Idiopathic Arthritis

Author Affiliations

Author Affiliations: Department of Orthopaedics, Southwest Hospital, Chongqing, China (xujianzhong1962@163.com).

JAMA. 2012;307(11):1140-1141. doi:10.1001/jama.2012.328

To the Editor: The study presented by Dr Otten and colleagues assessed factors associated with treatment response to etanercept in patients with juvenile idiopathic arthritis (JIA).1 They found that approximately one-third of the patients with JIA achieved an excellent response, which was associated with low baseline disability scores, low numbers of disease-modifying antirheumatic drugs used before initiating etanercept, and younger age at onset of JIA. One-third achieved a poor response, which was associated with systemic JIA and female sex.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×